Healthcare Pipeline-to-Revenue Financial Modeling
Build probability-weighted DCF models mapping biotech pipelines to risk-adjusted revenue
What You Can Do
You'll construct sophisticated DCF models that treat each clinical asset as a branching probability tree, weighting revenue contributions by phase-specific success rates (Phase I: 30%, Phase II: 33%, Phase III: 25-30%, FDA approval: 80-90%). This approach replaces deterministic sales projections with realistic scenario ranges, enabling you to value pre-revenue or early-revenue biotechs by their pipeline potential, regulatory trajectory, and time-to-market dynamics. The skill guides you through setting risk-adjusted discount rates (10-15% above pharma majors) and conducting sensitivity analyses that institutional investors expect.
Features
Weight each asset by clinical phase success rates and regulatory approval odds to create realistic outcome distributions
Account for Phase III duration, FDA review timelines, and label expansion scenarios in cash flow timing
Estimate maximum annual revenues using market size, competitive landscape, patient population, and pricing benchmarks
Model best-case, base-case, and downside scenarios with assigned probabilities for portfolio-level valuation
Apply biotech-specific WACC adjustments (10-15% premium) based on pipeline stage concentration and clinical risk
Isolate the value contribution of individual assets to identify key value drivers and catalysts
Pre-built tables for testing assumptions around trial success rates, peak sales, launch timing, and terminal growth rates
Compare relative valuations across clinical-stage companies with different pipeline compositions and risk profiles
Example Output
Example 1: Oncology Biotech with Phase II/III Pipeline
Asset 1 (Phase III, 2024 readout):
Success probability: 27.5% (Phase III 25% × FDA approval 90%)
Peak sales estimate: $450M
Contribution to NPV: $18.2M (27.5% × PV of $450M stream)
Asset 2 (Phase II, 2026 readout):
Success probability: 9.9% (Phase II 33% × Phase III 30% × FDA approval 85%)
Peak sales estimate: $280M
Contribution to NPV: $4.1M
Enterprise Value Range: $185M–$310M (base case $240M)
Example 2: Rare Disease Company with Concentrated Pipeline Model outputs a 40% probability of $120M peak sales vs. 60% probability of development discontinuation, yielding expected value of $48M discounted to $32M NPV at 12% risk-adjusted rate.
Example 3: Sensitivity Table Output Table showing NPV ranging from $140M to $380M as trial success rates vary ±10% and peak sales estimates shift ±20%, with color-coded heat map identifying highest-impact assumptions.
What's Included
- SKILL.md: Complete instruction file with probability-weighting methodology and biotech valuation frameworks
- DCF Model Template: Excel/Google Sheets template with pre-built formulas for probability-weighted cash flows and risk-adjusted discounting
- Phase Success Rate Reference Table: Industry-standard clinical trial success rates by indication and phase (FDA data and literature benchmarks)
- Peak Sales Estimation Checklist: Framework for gathering and validating market size, competitive, and pricing inputs
- Multi-Scenario Analysis Workbook: Pre-configured best/base/downside case models with assigned probability weights
- Sensitivity Dashboard Template: One-way and two-way sensitivity tables for testing key assumptions
Who It's For
- Equity research analysts covering healthcare and biotech sectors building detailed pipeline valuations for institutional clients
- Biotech CFOs and investor relations teams preparing financial models for fundraising, IPO roadshows, or investor presentations
- Healthcare-focused investment bankers valuing clinical-stage companies for M&A advisory or equity capital raises
- Venture capital and growth equity investors assessing early-stage drug candidates and portfolio company valuations
- Corporate development managers conducting in-licensing evaluations and pipeline acquisition analysis
Best For
- Clinical-stage company valuations — DCF modeling for pre-revenue or early-revenue biotechs with multi-asset pipelines
- Pipeline risk scenario analysis — Assessing enterprise value ranges across multiple regulatory and clinical outcomes
- IPO and fundraising models — Building investor-grade financial projections for Series D, IPO, or secondary offerings
- Peer relative valuation — Comparing pipeline-weighted valuations across similar clinical-stage companies
- Catalyst and sensitivity analysis — Identifying value drivers tied to upcoming trial readouts and regulatory interactions
- In-licensing and M&A evaluation — Probability-adjusted asset valuations for acquisition or partnership decisions
You might also like
You'll architect backtesting systems that separate genuinely profitable strategies from curve-fitted fantasies. The skill guides you through modeling realistic market microstructure, accounting for transaction costs, detecting survivorship bias, and stress-testing strategies across regime changes. You'll implement walk-forward validation, out-of-sample testing, and Monte Carlo simulations to predict actual live performance and identify where backtest results diverge from real trading outcomes.
by fission
You can systematically evaluate real estate acquisition opportunities by inputting property financials, market data, and deal terms into a standardized framework. The skill analyzes cap rates, cash flow projections, market fundamentals, and risk factors to generate consistent, comparable metrics across multiple deals. This enables you to quickly identify investment-worthy opportunities versus deals that fail fundamental criteria, while documenting your investment thesis for compliance and portfolio tracking.
by fission
You can construct rigorous development pro formas that model complex project dynamics—construction budgets, phased timelines, pre-leasing velocity, financing structures, and market assumptions—then run sensitivity analysis to show how changes in rent, construction costs, or hold periods impact returns. This skill produces defensible investment theses suitable for LP presentations, lender submissions, and institutional review committees by capturing interdependencies that simple models miss.
by fission
You can map individual holdings against multiple thematic investment frameworks simultaneously, generating transparency-rich alignment scores that reveal true thematic exposure. Unlike traditional ESG screening, this skill identifies positive exposure to specific trends and solutions, helping you track portfolio concentration within thematic segments, detect misaligned holdings, and quantify drift from stated investment mandates with measurable impact metrics.
by fission
You can rapidly evaluate multiple financing structures for M&A, recapitalizations, and growth transactions by modeling different capital stack configurations and comparing them against recent comparable transaction benchmarks. The skill helps you assess debt capacity, analyze covenant headroom across downside scenarios, and stress-test leverage under EBITDA decline, capex disruption, and refinancing risk—enabling you to present optimized structures that balance cost of capital, covenant flexibility, and stakeholder requirements in client presentations and pitch books.
by fission
You can systematically evaluate corporate bond issuers by synthesizing quantitative metrics (leverage ratios, cash flow coverage, liquidity), qualitative factors (management quality, competitive positioning, covenant protections), and market signals (credit spreads, relative value) into a cohesive credit opinion. This framework enables you to construct ratings that withstand peer review, document credit theses for investment committees, and respond to market events with quantified analytical support.
by fission
You can ingest multi-property portfolio data and generate comprehensive financial diagnostics, including performance metrics, peer benchmarking, concentration risk analysis, and stress-test scenarios across economic conditions. Claude systematizes the analysis of 10-500+ heterogeneous assets (varying property types, leverage, lease structures, and markets) to identify underperformers, quantify rebalancing impact, and deliver executive summaries with specific buy/sell/hold recommendations backed by financial modeling.
by fission
You can systematically analyze complex alternative fund portfolios by decomposing returns into alpha, beta, and fee components, then benchmark manager performance against peers. The skill processes manager letters, fund documents, and performance data to identify risk sources, flag operational red flags, and generate standardized due diligence matrices that support investment committee decisions across hedge funds, private equity, infrastructure, and real assets.
by fission